- Home
- BMR vs MGX Comparison
BMR vs MGX Comparison
Compare BMR & MGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMR
- MGX
- Stock Information
- Founded
- BMR 2009
- MGX 2018
- Country
- BMR Israel
- MGX United States
- Employees
- BMR N/A
- MGX N/A
- Industry
- BMR Computer Software: Prepackaged Software
- MGX
- Sector
- BMR Technology
- MGX
- Exchange
- BMR Nasdaq
- MGX NYSE
- Market Cap
- BMR 59.3M
- MGX 62.1M
- IPO Year
- BMR 2023
- MGX 2024
- Fundamental
- Price
- BMR $2.93
- MGX $1.79
- Analyst Decision
- BMR
- MGX Strong Buy
- Analyst Count
- BMR 0
- MGX 4
- Target Price
- BMR N/A
- MGX $13.00
- AVG Volume (30 Days)
- BMR 76.0K
- MGX 297.1K
- Earning Date
- BMR 06-10-2025
- MGX 05-13-2025
- Dividend Yield
- BMR N/A
- MGX N/A
- EPS Growth
- BMR N/A
- MGX N/A
- EPS
- BMR N/A
- MGX N/A
- Revenue
- BMR $3,064,000.00
- MGX $45,263,000.00
- Revenue This Year
- BMR N/A
- MGX N/A
- Revenue Next Year
- BMR N/A
- MGX $8.34
- P/E Ratio
- BMR N/A
- MGX N/A
- Revenue Growth
- BMR 5.33
- MGX N/A
- 52 Week Low
- BMR $1.86
- MGX $1.23
- 52 Week High
- BMR $6.71
- MGX $6.90
- Technical
- Relative Strength Index (RSI)
- BMR 59.44
- MGX 57.24
- Support Level
- BMR $2.54
- MGX $1.59
- Resistance Level
- BMR $3.00
- MGX $1.82
- Average True Range (ATR)
- BMR 0.16
- MGX 0.11
- MACD
- BMR 0.01
- MGX 0.02
- Stochastic Oscillator
- BMR 82.61
- MGX 88.61
About BMR Beamr Imaging Ltd.
Beamr Imaging Ltd is a video technology and image science software company. It is an innovator of video encoding, transcoding, and optimization solutions that enable high quality, performance, and unmatched bitrate efficiency for video and images. The company is conducted through one operating segment, the optimization technology for video and photo compression. The company operates in Israel, the United States, and the rest of the world, it derives a majority of its revenue from the United States.
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.